BioStem Technologies Inc. Announces New Stock Transfer Agent and Name/Symbol Change Update
Dec 22, 2017
OTC Disclosure News Service
Oakland Park, FL
BioStem Technologies, Inc. (OTC PINK: BSEM) (the “Company”) announced today that, it has chosen to remain operating under the name BioStem Technologies Inc and symbol, BSEM. The Company also announces the selection of V Stock Transfer, LLC, based in Woodmere, NY, as its new stock transfer agent, registrar and dividend disbursement and reinvestment agent effective January 5, 2018.
The Companies CFO, Jason Matuszewski stated, “Our Board of Directors has decided to transition to V Stock providing enhanced services for our shareholders, while also reducing the overall administrative costs. We expect this change to have a psotive impact in the interactions between BioStem Technologies and its shareholder base.”
Detailed information will be mailed electronically to BSEMs registered shareholders shortly. Shareholders are asked not to contact V Stock Transfer until after January 5, 2018. Shareholders may continue to contact the company’s current stock transfer agent and registrar, Transfer Online, through Thursday, January 4, 2018, for any shareholder related questions.
Beginning January 2018, shareholders may contact V Stock Transfer in several ways: by phone at 1-855-987-8625, via the Internet at www.vstocktransfer.com or by mail addressed to V Stock Transfer, LLC, 18 Lafayette Place, Woodmere, NY 11598.
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine. The Companys mission is to discover, develop and produce the most effective Pharmaceutical and Regenerative Medicine products in the world. The Company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “future,” “plan” or “planned,” “expects,” believe” or “projected.” These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company’s control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
BioStem Technologies, Inc.
Facebook: BioStem Technologies
Andrew Van Vurst
Copyright © 2017 OTC Markets. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.